Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.

[1]  F. Torti,et al.  Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. , 1983, Annals of internal medicine.

[2]  B. Zaret,et al.  Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance , 1983 .

[3]  J. Tepper,et al.  Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities , 1983, Cancer.

[4]  R. Bonow,et al.  A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. , 1983 .

[5]  J. Tepper,et al.  The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. , 1982, Annals of surgery.

[6]  R. D. Shuman,et al.  Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity. , 1981, The Johns Hopkins medical journal.

[7]  I. Murray,et al.  Radionuclide ejection fraction in doxorubicin cardiotoxicity. , 1981, Cancer treatment reports.

[8]  Michael V. Green,et al.  Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography. , 1981, Annals of internal medicine.

[9]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[10]  G. Ewy,et al.  1-year followup of cardiac status after adriamycin therapy. , 1979, Cancer treatment reports.

[11]  R. W. Roberts,et al.  Cyclophosphamide‐induced cardiomyopathy. A report of two cases and review of the english literature , 1979, Cancer.

[12]  H. von Melchner,et al.  Adriamycin cardiotoxicity: a survey of 1273 patients. , 1979, Cancer treatment reports.

[13]  L. Goldman,et al.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. , 1979, The New England journal of medicine.

[14]  M. Billingham,et al.  Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. , 1978, JAMA.

[15]  J. Mason,et al.  Anthracycline cardiomyopathy monitored by morphologic changes. , 1978, Cancer treatment reports.

[16]  I. Henderson,et al.  Serial studies of cardiac function in patients receiving adriamycin. , 1978, Cancer treatment reports.

[17]  S. Balcerzak,et al.  Systolic time intervals in monitoring adriamycin-induced cardiotoxicity. , 1978, Cancer treatment reports.

[18]  J. Mason,et al.  Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. , 1978, Cancer treatment reports.

[19]  J. Ritchie,et al.  Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. , 1978, Cancer treatment reports.

[20]  R. Benjamin,et al.  QRS voltage change with adriamycin administration. , 1978, Cancer treatment reports.

[21]  G. Ewy,et al.  Noninvasive cardiac evaluation of patients receiving adriamycin. , 1978, Cancer treatment reports.

[22]  R. Hutchinson,et al.  Systolic time intervals in monitoring for anthracycline cardiomyopathy in pediatric patients. , 1978, Cancer treatment reports.

[23]  J. A. Page,et al.  Cardiotoxicity of adriamycin and related anthracyclines. , 1976, Cancer treatment reviews.

[24]  V. Ferrans,et al.  ACUTE LETHAL CARDITIS CAUSED BY HIGH-DOSE COMBINATION CHEMOTHERAPY A Unique Clinical and Pathological Entity , 1976, The Lancet.

[25]  R. Slavin,et al.  Pathology of high dose intermittent cyclophosphamide therapy. , 1975, Human pathology.

[26]  J. Cassady,et al.  Radiation‐adriamycin interactions: Preliminary clinical observations , 1975, Cancer.

[27]  R. Benjamin,et al.  Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors , 1975 .

[28]  S. Balcerzak,et al.  Adriamycin cardiotoxicity in man. , 1974, Annals of internal medicine.

[29]  W. Fletcher,et al.  Evaluation of cardiac function during adriamycin therapy , 1974, Journal of surgical oncology.

[30]  J. Pitha,et al.  A clinicopathologic analysis of adriamycin cardiotoxicity , 1973, Cancer.

[31]  P. Neiman,et al.  High‐dose cyclophosphamide therapy for malignant disease. Toxicity, tumor response, and the effects of stored autologous marrow , 1972 .